Psychosocial impact of prognostic genetic testing in uveal melanoma patients: a controlled prospective clinical observational study.
Controlled prospective clinical observation trial
Prognostic genetic testing
Psycho-oncological intervention
Psychosocial impact
Uveal melanoma
Journal
BMC psychology
ISSN: 2050-7283
Titre abrégé: BMC Psychol
Pays: England
ID NLM: 101627676
Informations de publication
Date de publication:
31 Jan 2020
31 Jan 2020
Historique:
received:
18
06
2019
accepted:
10
01
2020
entrez:
2
2
2020
pubmed:
2
2
2020
medline:
4
6
2020
Statut:
epublish
Résumé
The risk of metastases in uveal melanoma can accurately be estimated through genetic analysis of the tumor. A growing number of patients decide to receive information on their prognosis, although this can be extremely burdensome. Studies on the psychosocial impact of testing are sparse. The objective of this study was to examine traits of patients opting for prognostication, to investigate its psychosocial impact and the use of psycho-oncological services over time. We further examined characteristics of patients utilizing these services and risk factors of prolonged psychological distress. This study is a non-randomized controlled prospective clinical observational trial. Patients availing for prognostication formed the test group, while those who opted out constituted the observational group. The psychosocial impact of genetic testing was assessed with the following variables: resilience, social support, fear of tumor progression, depression, general distress, health-related quality of life, estimation of the perceived risk, and the utilization of psycho-oncological interventions. Data were assessed at five different time points over a period of 12 months. We applied binary logistic regression analysis, multiple linear regressions and a mixed model. Of 175 patients, 63 decided to obtain prognostic information. Treatment method (enucleation > brachytherapy), lower social support and higher general distress could significantly predict patient's choice for prognostic testing. After result announcement, perceived risk of metastases was significantly increased in patients with poor prognosis, while it decreased in those with good prognosis. Overall, a significant decrease over time appeared concerning fear of progression, general distress, depression and anxiety. Mental quality of life increased over time. The utilization of psycho-oncological interventions increased significantly after prognostication; however, this was equivalent in the test and observational groups. Female sex, higher general distress and higher anxiety predicted greater use of psycho-oncological interventions. Availing of prognostic testing is not associated with poorer subsequent psychological well-being. It rather may help to alleviate distress and promote a more realistic risk perception. However, psychological support should be available to all patients, independent of prognosis and treatment, especially considering that patients with low social support and high distress increasingly opt for prognostication.
Sections du résumé
BACKGROUND
BACKGROUND
The risk of metastases in uveal melanoma can accurately be estimated through genetic analysis of the tumor. A growing number of patients decide to receive information on their prognosis, although this can be extremely burdensome. Studies on the psychosocial impact of testing are sparse. The objective of this study was to examine traits of patients opting for prognostication, to investigate its psychosocial impact and the use of psycho-oncological services over time. We further examined characteristics of patients utilizing these services and risk factors of prolonged psychological distress.
DESIGN AND METHODS
METHODS
This study is a non-randomized controlled prospective clinical observational trial. Patients availing for prognostication formed the test group, while those who opted out constituted the observational group. The psychosocial impact of genetic testing was assessed with the following variables: resilience, social support, fear of tumor progression, depression, general distress, health-related quality of life, estimation of the perceived risk, and the utilization of psycho-oncological interventions. Data were assessed at five different time points over a period of 12 months. We applied binary logistic regression analysis, multiple linear regressions and a mixed model.
RESULTS
RESULTS
Of 175 patients, 63 decided to obtain prognostic information. Treatment method (enucleation > brachytherapy), lower social support and higher general distress could significantly predict patient's choice for prognostic testing. After result announcement, perceived risk of metastases was significantly increased in patients with poor prognosis, while it decreased in those with good prognosis. Overall, a significant decrease over time appeared concerning fear of progression, general distress, depression and anxiety. Mental quality of life increased over time. The utilization of psycho-oncological interventions increased significantly after prognostication; however, this was equivalent in the test and observational groups. Female sex, higher general distress and higher anxiety predicted greater use of psycho-oncological interventions.
DISCUSSION
CONCLUSIONS
Availing of prognostic testing is not associated with poorer subsequent psychological well-being. It rather may help to alleviate distress and promote a more realistic risk perception. However, psychological support should be available to all patients, independent of prognosis and treatment, especially considering that patients with low social support and high distress increasingly opt for prognostication.
Identifiants
pubmed: 32005293
doi: 10.1186/s40359-020-0371-3
pii: 10.1186/s40359-020-0371-3
pmc: PMC6995105
doi:
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
8Subventions
Organisme : Deutsche Krebshilfe
ID : 110961
Références
Soc Sci Med. 1993 Mar;36(6):725-33
pubmed: 8480217
Int J Retina Vitreous. 2016 Feb 1;2:4
pubmed: 27847622
Klin Monbl Augenheilkd. 2013 Jul;230(7):686-91
pubmed: 23877823
Biomarkers. 2019 Mar;24(2):134-140
pubmed: 30265160
Psychooncology. 2012 Jan;21(1):29-42
pubmed: 21072753
J Oncol. 2018 Mar 20;2018:5253109
pubmed: 29755525
Melanoma Res. 2013 Dec;23(6):481-8
pubmed: 24048223
Z Psychosom Med Psychother. 2009;55(3):248-62
pubmed: 19886593
Clin Cancer Res. 2010 Dec 15;16(24):6083-92
pubmed: 20975103
Cancer. 2008 Sep 1;113(5):956-65
pubmed: 18618513
Psychooncology. 2015 Nov;24(11):1485-91
pubmed: 25873360
Arch Soc Esp Oftalmol. 2008 May;83(5):301-6
pubmed: 18464179
Ophthalmology. 2007 Dec;114(12):2309-15
pubmed: 17498805
Br J Ophthalmol. 2013 Nov;97(11):1471-4
pubmed: 24037609
Cancer. 1998 May 15;82(10):1904-8
pubmed: 9587123
Med Care. 1996 Mar;34(3):220-33
pubmed: 8628042
Psychooncology. 2017 Jul;26(7):917-926
pubmed: 27440317
Acta Ophthalmol Scand. 2004 Feb;82(1):25-31
pubmed: 14982042
JAMA Ophthalmol. 2018 Apr 1;136(4):356-363
pubmed: 29470565
Lancet. 1996 May 4;347(9010):1222-5
pubmed: 8622452
Arch Ophthalmol. 2006 Feb;124(2):226-38
pubmed: 16476893
Br J Cancer. 2012 Mar 13;106(6):1171-6
pubmed: 22353812
Soc Sci Med. 2002 May;54(10):1463-70
pubmed: 12061481
Acta Ophthalmol. 2018 Jun;96(4):e421-e426
pubmed: 29369538
Psychooncology. 2006 Dec;15(12):1077-85
pubmed: 16634126
Health Psychol. 2019 Mar;38(3):187-195
pubmed: 30762398
Violence Vict. 2006 Aug;21(4):499-506
pubmed: 16897916
Health Expect. 2011 Dec;14(4):383-96
pubmed: 21029286
Fam Cancer. 2006;5(1):61-75
pubmed: 16528610
Psychooncology. 2013 Feb;22(2):417-25
pubmed: 22135240
J Psychosom Res. 2005 Jun;58(6):505-11
pubmed: 16125517
Acta Ophthalmol. 2018 Jun;96(4):331-347
pubmed: 29105334
Ophthalmology. 2017 May;124(5):609-618
pubmed: 28159380
Psychooncology. 2005 Dec;14(12):1060-74
pubmed: 15937976
Eye (Lond). 2016 Dec;30(12):1598-1605
pubmed: 27589051
JAMA Ophthalmol. 2016 Jan;134(1):51-6
pubmed: 26539659
Eye (Lond). 2000 Dec;14(Pt 6):839-46
pubmed: 11584839
Psychooncology. 2013 Apr;22(4):837-44
pubmed: 22473731
Psychooncology. 2013 Mar;22(3):598-604
pubmed: 22315183
Health Expect. 2007 Sep;10(3):248-58
pubmed: 17678513
J Genet Couns. 2009 Jun;18(3):265-74
pubmed: 19421848
Eye (Lond). 2009 Mar;23(3):581-5
pubmed: 18344957
Eur J Cancer Care (Engl). 2010 Jul;19(4):476-81
pubmed: 19912303